Advertisement

Cytotoxic Chemotherapy and Endocrine Therapy for Hepatocellular Carcinoma

  • Daniel Palmer
  • Philip J. Johnson
Chapter

Abstract

For the minority of patients with hepatocellular carcinoma (HCC), surgical therapy, including transplantation, or local ablation may offer the prospect of cure (see Chapters 9–17). However, these treatments are typically constrained by size and/or number of tumours as well as liver dysfunction and other comorbidities.

Keywords

Cytotoxic chemotherapy Endocrine therapy Doxorubicin Tamoxifen Somatostatin analogues Drug resistance 

References

  1. 1.
    Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H (1975) Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 36:1250–1257CrossRefPubMedGoogle Scholar
  2. 2.
    Vogel CL, Bayley AC, Brooker RJ, Anthony PP, Ziegler JL (1977) A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39:1923–1929CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM (1978) Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1:1006–1009CrossRefPubMedGoogle Scholar
  4. 4.
    Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149–2156CrossRefPubMedGoogle Scholar
  5. 5.
    Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK (1980) Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 46:2717–2722CrossRefPubMedGoogle Scholar
  6. 6.
    Williams R, Melia WM (1980) Liver tumours and their management. Clin Radiol 31:1–11CrossRefPubMedGoogle Scholar
  7. 7.
    Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 51:206–210CrossRefPubMedGoogle Scholar
  8. 8.
    Chlebowski RT, Tong M, Weissman J, Block JB, Ramming KP, Weiner JM, Bateman JR, Chlebowski JS (1984) Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer 53:2701–2706CrossRefPubMedGoogle Scholar
  9. 9.
    Choi TK, Lee NW, Wong J (1984) Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53:401–405CrossRefPubMedGoogle Scholar
  10. 10.
    Falkson G, MacIntyre JM, Schutt AJ, Coetzer B, Johnson LA, Simson IW, Douglass HO Jr (1984) Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 2:581–584PubMedGoogle Scholar
  11. 11.
    Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer 54:970–977CrossRefPubMedGoogle Scholar
  12. 12.
    Colombo M, Tommasini MA, Del Ninno E, Rumi MG, De Fazio C, Dioguardi ML (1985) Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicin. Liver 5:336–341PubMedGoogle Scholar
  13. 13.
    Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L (1985) Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer 56:2751–2755CrossRefPubMedGoogle Scholar
  14. 14.
    Melia WM, Johnson PJ, Williams R (1987) Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71:5Google Scholar
  15. 15.
    Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479–483CrossRefPubMedGoogle Scholar
  16. 16.
    Johnson PJ, Dobbs N, Kalayci C, Aldous MC, Harper P, Metivier EM, Williams R (1992) Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 65:751–755PubMedGoogle Scholar
  17. 17.
    Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mössner J, Berr F (2000) A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 11:113–114CrossRefPubMedGoogle Scholar
  18. 18.
    Hong RL, Tseng YL (2003) A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 51:433–438PubMedGoogle Scholar
  19. 19.
    Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM (1985) 4’Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 3:1535–1540PubMedGoogle Scholar
  20. 20.
    Pohl J, Zuna I, Stremmel W, Rudi J (2001) Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 47:359–365CrossRefPubMedGoogle Scholar
  21. 21.
    Lai KH, Tsai YT, Lee SD, Ng WW, Teng HC, Tam TN, Lo GH, Lin HC, Lin HJ, Wu JC, et al (1989) Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol 23:54–56CrossRefPubMedGoogle Scholar
  22. 22.
    Ravry MJ, Omura GA, Bartolucci AA, Einhorn L, Kramer B, Davila E (1986) Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70:311–312PubMedGoogle Scholar
  23. 23.
    Zaniboni A, Simoncini E, Marpicati P, Marini G (1988) Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. Br J Cancer 57:319PubMedGoogle Scholar
  24. 24.
    Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S, Uehara K, Inayoshi J, Yokoyama J, Ishimoto Y, Asakura H (2001) Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 16:452–459CrossRefGoogle Scholar
  25. 25.
    Leung TW, Feun L, Posey J, Stagg RJ, Levy MD, Venook AP (2002) A phase II study of T138067-sodium in patients (pts) with unresectable hepatocellular carcinoma (HCC) [Abstract 572]. Proc Am Soc Clin Oncol 21Google Scholar
  26. 26.
    Posey J, Johnson P, Mok T, Hirmand M, Dahlberg S, Kwei L, Leung T (2005) Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23, No. 16S, Part I of II (June 1 Supplement): 4035Google Scholar
  27. 27.
    Stuart K, Tessitore J, Rudy J, Clendennin N, Johnston A (1999) A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 86:410–414CrossRefPubMedGoogle Scholar
  28. 28.
    Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P (1999) A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 44:307–311CrossRefPubMedGoogle Scholar
  29. 29.
    Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069–3075CrossRefPubMedGoogle Scholar
  30. 30.
    Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681PubMedGoogle Scholar
  31. 31.
    Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532–1538CrossRefPubMedGoogle Scholar
  32. 32.
    Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, Nastasi G (1997) Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 33:1784–1788CrossRefPubMedGoogle Scholar
  33. 33.
    Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M (2003) Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 23:1891–1897PubMedGoogle Scholar
  34. 34.
    Yang TS, Lin YC, Chen JS, Wang HM, Wang CH (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750–756CrossRefPubMedGoogle Scholar
  35. 35.
    Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taïeb J (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109:1384–1390CrossRefPubMedGoogle Scholar
  36. 36.
    Farinati F, Salvagnini M, de Maria N, Fornasiero A, Chiaramonte M, Rossaro L, Naccarato R (1990) Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 11:297–301CrossRefPubMedGoogle Scholar
  37. 37.
    Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonte M, Naccarato R (1992) Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 37:659–662CrossRefPubMedGoogle Scholar
  38. 38.
    Castells A, Bruix J, Brú C, Ayuso C, Roca M, Boix L, Vilana R, Rodés J (1995) Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109:917–922CrossRefPubMedGoogle Scholar
  39. 39.
    Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC, Asian-Pacific Hepatocellular Carcinoma Trials Group (2002) High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36:1221–1226CrossRefPubMedGoogle Scholar
  40. 40.
    CLIP Group (1998) Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 352:17–20CrossRefGoogle Scholar
  41. 41.
    Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J (2000) Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 95:218–222CrossRefPubMedGoogle Scholar
  42. 42.
    Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, Manno M, Bertani H, Dugani A, Manenti F (2001) Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 84:881–885CrossRefPubMedGoogle Scholar
  43. 43.
    Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ (1995) Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 21:1535–1542PubMedGoogle Scholar
  44. 44.
    Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils J (1998) Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 16:411–417PubMedGoogle Scholar
  45. 45.
    Melia WM, Johnson PJ, Williams R (1987) Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71:1213–1216PubMedGoogle Scholar
  46. 46.
    Uchino J, Une Y, Sato Y, Gondo H, Nakajima Y, Sato N (1993) Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol 16:206–209CrossRefPubMedGoogle Scholar
  47. 47.
    Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R (2009) PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 27(28):4656–4663.Google Scholar
  48. 48.
    Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P (2006) Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 132:699–708CrossRefPubMedGoogle Scholar
  49. 49.
    Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Läderach U, Wiedenmann B (1999) Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45:766–774CrossRefPubMedGoogle Scholar
  50. 50.
    Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON (1998) Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 42:442–447CrossRefPubMedGoogle Scholar
  51. 51.
    Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC (2002) A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36:687–691CrossRefPubMedGoogle Scholar
  52. 52.
    Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE; HECTOR Study Group (2007) Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45:9–15CrossRefPubMedGoogle Scholar
  53. 53.
    Oldhafer KJ, Chavan A, Frühauf NR, Flemming P, Schlitt HJ, Kubicka S, Nashan B, Weimann A, Raab R, Manns MP, Galanski M (1998) Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 29:953–959CrossRefPubMedGoogle Scholar
  54. 54.
    Lai EC, Lo CM, Fan ST, Liu CL, Wong J (1998) Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133:183–188CrossRefPubMedGoogle Scholar
  55. 55.
    Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, Peng FK (1995) Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82:122–126CrossRefPubMedGoogle Scholar
  56. 56.
    Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I (1994) Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20:295–301CrossRefPubMedGoogle Scholar
  57. 57.
    Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, Kakumoto Y, Saitsu H, Yamada R, Oosaki Y, Arii S, Okamoto E, Monden M, Ryu M, Kusano S, Kanematsu T, Ikeda K, Yamamoto M, Saoshiro T, Tsuzuki T. (1996) A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87:206–211PubMedGoogle Scholar
  58. 58.
    Yamamoto M, Arii S, Sugahara K, Tobe T (1996) Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 83:336–340CrossRefPubMedGoogle Scholar
  59. 59.
    Ono T, Nagasue N, Kohno H, Hayashi T, Uchida M, Yukaya H, Yamanoi A (1997) Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 24(2 Suppl 6):S6–18–S6–25Google Scholar
  60. 60.
    Kohno H, Nagasue N, Hayashi T, Yamanoi A, Uchida M, Ono T, Yukaya H, Kimura N, Nakamura T (1996) Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 43:1405–1409PubMedGoogle Scholar
  61. 61.
    Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334:1561–1567Google Scholar
  62. 62.
    Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H (2001) Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963–967Google Scholar
  63. 63.
    Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50:958–968CrossRefPubMedGoogle Scholar
  64. 64.
    Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ, To KF (2009) TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patient survival and chemoresistance. Int J Cancer 124:644–652CrossRefPubMedGoogle Scholar
  65. 65.
    Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076PubMedGoogle Scholar
  66. 66.
    Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61:3535–3540PubMedGoogle Scholar
  67. 67.
    Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerciolini R, Pierce JE, Hossfeld DK (2004) Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22(July 15 Suppl), 4089.Google Scholar
  68. 68.
    Berlin JD, Powell ME, Su Y, Horton L, Short S, Richmond A, Kauh JS, Staley CA, Mulcahy M, Benson AB (2008) Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): a phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates [Abstract 4592]. Clin Oncol 26(May 20 Suppl)Google Scholar
  69. 69.
    Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA (2003) Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301:94–96CrossRefPubMedGoogle Scholar
  70. 70.
    Abou-Alfa G, Johnson P, Knox J, et al (2007) Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the 2007 meeting of the European Cancer Organization. European Journal of Cancer Supplements [Abstract 3500]. 5:259Google Scholar
  71. 71.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMedGoogle Scholar
  72. 72.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62CrossRefPubMedGoogle Scholar
  73. 73.
    Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898–1903CrossRefPubMedGoogle Scholar
  74. 74.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMedGoogle Scholar
  75. 75.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMedGoogle Scholar
  76. 76.
    Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446–452CrossRefPubMedGoogle Scholar
  77. 77.
    Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15:1661–1666CrossRefPubMedGoogle Scholar
  78. 78.
    Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927–934CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Daniel Palmer
    • 1
  • Philip J. Johnson
    • 1
  1. 1.Clinical Trials Unit, CRUK Institute for Cancer StudiesUniversity of BirminghamBirminghamUK

Personalised recommendations